1-1 of 1
chronic lymphocytic leukemia refractory
Close
Sort by
Journal Articles

A phase 1 study of lenalidomide and ibrutinib in combination with rituximab in relapsed and refractory CLL

Clinical Trials & Observations
Chaitra Ujjani, Hongkun Wang, Alan Skarbnik, Neel Trivedi, Pari Ramzi, Nadia Khan, Bruce D. Cheson
Journal: Blood Advances
Blood Adv (2018) 2 (7): 762–768.
https://doi.org/10.1182/bloodadvances.2017015263
Published: 2018